Insulet Corporation (PODD) Stock Analysis 2026

HealthcareMedical Devices
$141.10
as of 2026-10-16
-61.2% (52-week)50D MA $154.33  |  200D MA $212.94

BriMind AI Score

Proprietary
45
Neutral
Price CAGR
13.4%
1Y Return
-57.0%
Analyst Upside
+27.1%
Rev Growth
23.5%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

PODD Revenue & Profitability Breakdown

This chart shows how PODD's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$3.05B
Cost of Revenue
-$883.2M
Gross Profit
$2.17B71.1% margin
Operating Expenses
-$1.68B
Operating Income
$494.0M16.2% margin
Tax & Other
-$118.7M
Net Income
$375.3M12.3% margin
Gross Margin
71.1%
Operating Margin
16.2%
Net Margin
12.3%

Key Financial Metrics

Insulet Corporation trades at a trailing P/E of 27.79x, generates $236.9M in free cash flow, runs a debt/equity ratio of 66.69, and converts shareholder equity into profit at a 26.0% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$10.27B
P/E (Trailing)
27.79
P/E (Forward)
19.21
PEG Ratio
1.17
Price / Book
7.22
Revenue
$3.05B
Revenue Growth
23.5%
Earnings Growth
328.6%
EPS (Trailing)
$5.33
EPS (Forward)
$7.71
Gross Margin
71.1%
Operating Margin
16.2%
Net Margin
12.3%
Return on Equity
26.0%
Return on Assets
9.7%
Free Cash Flow
$236.9M
Debt / Equity
66.69
Current Ratio
2.48
Quick Ratio
1.51
Beta
1.09
Dividend Yield
None
Payout Ratio
0.0%
Insider Ownership
0.3%
Inst. Ownership
107.0%
Short % Float
6.0%
Book Value / Share
$20.51

Wall Street Analyst Consensus

Wall Street analysts covering Insulet Corporation currently haven't converged on a clear consensus rating, with a mean 12-month price target of $171.91 (+21.8% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Mean Target$171.91+21.8% upside

Intrinsic Value Estimates for PODD

We use 3 valuation models to estimate PODD's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

Technical Price Signals

PODD is currently in a death cross pattern, trading below its 50-day average of $154.33 and below its 200-day average of $212.94. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$141.10
50-Day MA
$154.33
▼ Price below
200-Day MA
$212.94
▼ Price below
Death Cross Pattern
Price below both MAs — bearish signal
Read the full PODD in-depth report
Seven-method valuation, AI Score, blended price target, and a 5-year Monte Carlo simulation for PODD.

Compare PODD with Peers

PODD vs DXCMInsulet vs DexCom — Which Diabetes Tech Stock Wins?
MASI vs ISRGMasimo vs Intuitive Surgical — Medical Electronics vs R
PODD vs TNDMInsulet vs Tandem — Tubeless Patch Pump vs Tubed Pump R
PODD vs TNDMInsulet vs Tandem Diabetes Care — Which Insulin-Pump Ma
BSX vs PODDBoston Scientific vs Insulet — Diversified Device Growt

More Healthcare Stock Analysis

In-depth reports on companies operating alongside PODD — business models, bull and bear cases, and the metrics that matter.

DXCMDexCom, Inc.Medical DevicesBSXBoston Scientific CorporationMedical DevicesSYKStryker CorporationMedical DevicesZBHZimmer Biomet Holdings, Inc.Medical DevicesGEHCGE HealthCare Technologies Inc.Medical DevicesMDTMedtronic plcMedical DevicesEWEdwards Lifesciences CorporationMedical DevicesSTESTERIS plcMedical Devices

Unlock the Full PODD Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis